Chronic immune thrombocytopenic purpura in children : Clinical presentations and management

##plugins.themes.academic_pro.article.sidebar##

Published Oct 30, 2024
https://doi.org/10.62438/tunismed.v102i11.5117
Download
pdf
Vol. 102 No. 11 (2024): Tunis Med nov 2024

##plugins.themes.academic_pro.article.main##

Ines Maaloul
Department of pediatrics. Hedi Chaker Hospital, Sfax. Faculty of medecine of Sfax. Tunisia
Roeya Kolsi
Department of pediatrics. Hedi Chaker Hospital, Sfax. Faculty of medecine of Sfax. Tunisia
Mourad Chaari
Laboratory of Hematology. Hedi Chaker Hospital, Sfax. Faculty of medecine of Sfax, Tunisia
Salma Ben Ameur
Department of pediatrics. Hedi Chaker Hospital, Sfax. Faculty of medecine of Sfax. Tunisia
Hajer Aloulou
Department of pediatrics. Hedi Chaker Hospital, Sfax. Faculty of medecine of Sfax. Tunisia
Thouraya Kamoun
Department of pediatrics. Hedi Chaker Hospital, Sfax. Faculty of medecine of Sfax. Tunisia

Abstract

Objective: the aim of this study is to report epidemiological data, clinical presentations and management of chronic immune thrombocytopenic purpura  (ITP)  in a single center in south of TUNISIA.


Methods: retrospective study collecting all cases of chronic ITP among children aged less than 14 years, in a department of pediatrics in south of Tunisia during a period of 13 years (from 1st January 2010 to 31 December 2022)


Results: during the study period, 72 newly diagnosed ITP were recorded; 11 patients evolves chronic ITP (12 ,5%). They were 6 boys and 5 girls.   Two patients were aged more than 10 years at the onset of the disease.  Symptoms in the chronic stage were mucocutaneous bleeding. One patient developed post traumatic cerebral hemorragia.  Three patients had severe form, and required second-line therapy. Two patients requested Eltrombopag  with good response.


One patient had spontaneous recovery after 3 years of follow up.


Conclusion: Management of chronic ITP represents a real challenge for pediatrician. Currently, there are some recommendations and guidelines which can guide management strategy of severe forms of Chronic ITP.


 

Keywords:

chronic immune thrombocytopenic purpura, children, management

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. - Imbach P, Kühne T, Müller D, et al. Childhood ITP: 12 months follow-up data from the prospective registry I of the Intercontinental Childhood ITP Study Group (ICIS). Pediatr Blood Cancer. 2006 ;46(3):351‑6.
  2. -Donato H, Picón A, Martinez M, et al. Demographic data, natural history, and prognostic factors of idiopathic thrombocytopenic purpura in children: a multicentered study from Argentina. Pediatr Blood Cancer. 2009 ;52(4):491‑6.
  3. - Kim TO, Despotovic J , Lambert MP . Eltrombopag for use in children with immune thrombocytopenia. Blood Advances 2018 ; 2(4): 454–4
  4. - Rodeghiero F, Stasi R, Gernsheimer T et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386‑93.
  5. - Buchanan GR, Adix L. Grading of hemorrhage in children with idiopathic thrombocytopenic purpura. J Pediatr. 2002;141(5):683 8.
  6. - Neunert C, Terll DR, Arnold DM, et al. American society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 2019 ;3 (23) : 3829-66
  7. - Leverger G, Petit A, Fasola S, Landman Parker J, Favier R. Les thrombopénies génétiques. Arch Pediatr 2010 ;17(8) :1185-91
  8. - Terell DR, Beebe LA, Neas BR, Vesely SK, Segal JB, Georges JN. Prevalence of primary immune thrombocytopenia in okhlahoma. Am J Hematol 2012 ;87(9) :848-52
  9. - Blanchette VS. Childhood chronic immune thrombocytopenic purpura . Blood Rev 2002 ;16(1) :23-6
  10. - Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocyopenia. Blood 2010,115,168-186
  11. - Evim MS, Baytan B, Gunes AM. Childhood immune thrombocytopenia : long terme follow up data evaluated by the criteria of the international working group on immune thrombocytopenic purpura. Turk J Hematol 2014 ;31 :32-39
  12. -Leverger G. Purpuras thrombopéniques immunologiques chroniques de l’enfant : actualités et nouvelles approches thérapeutiques. Réalités pédiatriques 2013 : 1-5.
  13. -Emmerich F, Bal G, Barakat A, et al. High level serum cell activating factor and promotor polymorphisms in patients with idiopathic thrombocytopenic purpura . Br J Haematol 2007 ;136(2) : 309-14
  14. - Rosu VE, Rosu ST, Ivanov V, et al. Predictors factors for chronicity in immune thrombocytopenic purpura in children. Children 2023, 10,911
  15. - Kühne T. Diagnosis and management of immune thrombocytopenia in childhood. Hamostaseologie.2017;37(1):36 44.
  16. - Grace RF, Lambert MP. An update on pediatric ITP: differentiating primary ITP, IPD, and PID. Blood. 2022;140(6):542 55.
  17. - Neunert CE, Buchanan GR, Imbach P et al. Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS). Blood. 2013;121(22):4457 62.
  18. - Lambert MP. Childhood ITP: knowing when to worry? Blood. 2009;114(23):4758 9.
  19. - Psaila B, Petrovic A, Page LK, Menell J, Schonholz M, Bussel JB. Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases. Blood 2009;114(23):4777 83.
  20. - Boutroux H, Leblanc T, Courcoux MF, Pasquet M, Aladjidi N, Leverger G. Mise au pint : le purpura thrombopénique immunologique de l’enfant. Journal de pédiatrie er de puériculture 2018, 31(2) : 79-85.
  21. - Liang Y, Zhang L, Gao J, Hu D, Ai Y. Rituximab for children with immune thrombocytopenia: a systematic review. PloS One. 2012;7(5):e36698.
  22. - Al-Samkari H, Grace RF, Kuter DJ. The role of romiplostim for pediatric patients with immune thrombocytopenia. Ther Adv Hematol. 2020;11:2040620720912992.
  23. - Grainger JD, Locatelli F, Chotsampancharoen T, et al. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet Lond Engl. 2015;386(10004):1649 58.
  24. -Tait RC, Evans DI. Late spontaneous recovery of chronic thrombocytopenia. Arch Dis Child.1993;68(5):680 1.
  25. - Ducassou S, Gourdonneau A, Fernandes H, et al. Second-line treatment trends and long-term outcomes of 392 children with chronic immune thrombocytopenic purpura: the French experience over the past 25 years. Br J Haematol. 2020;189(5):931 42.
  26. - Chotsampancharoen T, Sripornsawan P, Duangchoo S, Wongchanchailert M, McNeil E. Clinical outcome of childhood chronic immune thrombocytopenia: A 38-year experience from a single tertiary center in Thailand. Pediatr Blood Cancer.2017;64(11).
  27. -Aronis S, Platokouki H, Mitsika A, Haidas S, Constantopoulos A. Seventeen years of experience with chronic idiopathic thrombocytopenic purpura in childhood. Is therapy always better? Pediatr Hematol Oncol. 1994;11(5):487 98.
  28. -Tamary H, Kaplinsky C, Levy I, et al. Chronic childhood idiopathic thrombocytopenia purpura: long-term follow-up. Acta Paediatr Oslo Nor1994;83(9):931 4.